title: Polymorphisms, hypertension and thiazide diuretics.
abstract: It is 10 years since the discovery of the human genome; however, the study of the influence of genetic variants on drug effect - pharmacogenomics - has so far failed to create a major impact on day-to-day prescription practices. In the present article we analyze the main findings in candidate gene variants, gene combinations and whole-genome scans in relation to diuretic treatment. A critical analysis of the main reasons for some contrasting results will be discussed. The hypertension phases, in clinical trials dealing with genes and related pathophysiological mechanisms, may account for these inconsistent findings. The use of previously untreated versus treated patients is addressed. Finally, a positive study with a new genetic molecular strategy is described.
authors: San Raffaele Scientific Institute, OU of Nephrology & Dialysis, Università Vita-Salute, San Raffaele Hospital, Milan, Italy. citterio.lorena@hsr.it
authors: Lorena
authors: L
authors: Citterio
authors: Chiara
authors: C
authors: Lanzani
authors: Paolo
authors: P
authors: Manunta
mesh_terms: D054316:Biomarkers, Pharmacological; D002148:Calmodulin-Binding Proteins / Q000235:genetics; D004232:Diuretics / Q000493:pharmacokinetics / Q000627:therapeutic use*; D056726:Genetic Association Studies; D055106:Genome-Wide Association Study; D006801:Humans; D006852:Hydrochlorothiazide / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006973:Hypertension / Q000188:drug therapy*; D010042:Ouabain / Q000378:metabolism; D011110:Polymorphism, Genetic; D000099291:Adducins
chemical_list: D054316:Biomarkers, Pharmacological; D002148:Calmodulin-Binding Proteins; D004232:Diuretics; D006852:Hydrochlorothiazide; D010042:Ouabain; D000099291:Adducins